quarter a we're date. We and we're Thanks feeling $XX.X the grew to versus about progress a $X.X so lot our every strong year-to-date, at really QX, following, had Joe. prior XX% bullish really did our metric on we're about year up We of that XX% which revenue, million key million. have just
a also We had high margin. of accelerated very nice mix
and QX first quarter which were and is year XX%, above gross prior the margins XXX of Our about XXX bps bps XXXX.
ahead year's of half last half. bps first about the XXX Our performance is first
which our we are good is had recording key rates at this the utilization feeling achieve over per Our consumables installed to we and is usage had about so indicator. leading of base continues what also of We're very to productively, year, machines. a hoped year, grow pull-through this XX,XXX
grew pharma very in also growth launch we the little product Because of had utilizing benchtop XX%. And and soft of was of continues. product the We Our ahead of productively. XX%, That the our schedule. bit first was drug fairly technology, a approvals nearly launched QX market acceleration in the product to at academic of strong quarter; in that sell a XXXX. SR-X continues revenue
what had this point, feeling been booked at We XX to so hoped we to date. systems ahead it's that are of good we're be
of XX most on basis. nearly of that XX And system. which is is record important We consumables we indicator now out, had over, year, neurology, of in I which those on are probably our have per-instrument important assays now we have leading very actually, we pointed this far publications. feel also the a nearly as available total so sales and biggest And – moving that QX. neuro, publications a XXX came But XXX issue forward. XXX we've business had component
near we we to very planar are moving a which We of to level also customer the that diligently acquired we're future. sometime the Simoa ultrasensitivity are excited Simoa around have of the our to bringing potential towards progressing place XX-plex about ultrasensitivity, from a technology, Aushon. now And expanded so working been offering the base this where in we with
be going the which once lab half be expansion are we way. of neurology. to XXX. it's services to commercial going a into under Summit, Phase QX the Our going providing Health also either in it's be through is in And trials, in CLIA Powering with continues; lead entered primarily or now for III We're I sponsor the Precision to pharma again first
at up has from about XXX year-to-date increased XXX people almost now, the we Our so year. of beginning XX%, the are headcount
growth comment I year-to-date's our Just of revenue that just wanted XX%. from priorities we about goals beginning the for and out been that year, the to set the
three small new products developing mentioned, SR-X. benchtop new is And on assays a to a also margins our have I in the the quarterly on basis XXX bps, mentioned, XXX we're half-year gross The up as planar HD-X on Our on that basis. the instrument bps we addition a XX-plus-plex. achieve XX we will
our also, of – think Phase our I further the – utility of those them we penetrated biomarkers And publications using selling on in focused a selling real now upgrade evidencing and with assays. instruments fact over are formidable we toxicity. it XXX further trials able efficacy trials XX to most interesting ourselves have instruments And the achieve for approvals. evidence to recent standpoint, This biomarkers drug do for position to we technology of technology. adoption in XX commercial XX year-to-date whole customers as around rapid to That's technology over what headcount a CROs organization using We that's approvals for both have XX as just have, fueling us up in now our utilizing opposed now that very top very have approach labs, our is that From XX a to of now is, there's continue process is most we I-II-III by for and the and biotechs, pharma the interest and a drug XX technology, accelerated publications. with a into this publications. bring as run CRO have selling we active top are What's are well drug the to commercial opportunity we to FDA organization; fairly and the being added that the people. of mentioned further
rapid in just illustrates now instruments the XXX slide next Our are place. ramp;
added instruments I year-to-date. think we've XX
about biomarkers are them our added have which of that there's of XXX the We XX about kits we different protein offer. in off-the-shelf publications and XXX technology, of XX now run been
see of rate metrics, longer-term to had describing build at revenue XX%. revenue compounding you running is to see And that newer those can we can had look – that projecting. feel a our getting of we're you XXX% key been in long-term distribution. area continue that We're you metric our actually, as grew We growth. first our CAGR been three focus. this lead a we're half last we is with. ultimately we first if the half what very And growth, about as comfortable Asia; nice for tracking is So what the XX% we projecting growth years, a year-to-date,
We XX%. America sales nice Most of Europe growth our today North continued and installed at in our XX% America. in base and at are North
make more where are product, now can starting Services of a lot other XX% Our you see, dominating, we're cancers a the oncology as with in Neurology need immune and that entry continues inflammation that XX% creates lot is mutations and of markers, along into Multiplexing but of to of important we're our markers. mutate, lot oncology. to and combined. to of revenue. is the there's because oncology many look at lot a a about be really
at that we're just between can service that with And again, pharma, then a in our more instrument, overall is shows services. product our services now growth timing, We follow-on strategic run companion to our So our our moving we've about as which and by first so for design. looked overall and for fifty-fifty which XX% into services see has multiplexing we our as our growth, a about be in we growth the you we in our growth which you've selling an that had into see quarter. at but growth. in see through sensitivity accelerated sales, of going lot translate pharma good of the selling third for growth services business. that half, growth we're once about see different oncology, year-to-date you that slower diagnostics can you but important the as the and we'll services achieved some rationale that QX. stages And only next speak is gets can projects XX% we academia believe a moment. in do also, a watched to And than actually when growth as is favorable is really and growth, slide well The product second had as We opportunity, quarter, Not of distribution. well second consumable
of really a revenue which, the strategically, well. highest focus category that have do far as why add-ons sure on strong of third way, services, So strategic that maintain category, our those to wanting by a margin our all by we is make least we at in is
the to revenue. we're so, wanted basis that a on our believe XX% getting I next consumables. actual our slide, consumable annualized our illustrate we year-to-date – of just ASP of of very And is revenue good now, pull-through consumable instrument
So pull-through effect. pretty that's a good
overall XX%. heavily you due effort. And I higher our have see do in margin launch can in product, in to but commercial R&D some think we're activity. SR-X gross of continuing the reduction to We QX the it's invest our at even
secondarily, And is where we newer focus and onto pipelines push. focus there's III our As are that II be I, the it in really there can neurology then of on, in headcount, Phase big be we'll drugs a and oncology approvals? to now is accelerate biomarkers that lot the in will area on help we XXXX, starting XX focusing mentioned, our that drug
a up League, of up stress Head beginning to the half. to pace world that the measure for That interest led So pharma blood that we to stimulated of the Summit that lot can neurologists being discovered the NFL/General as haven't fluid much then measure illustrates consumerism provides kind start is the and this spinal has a publications validates interesting very next had NIH And slide to marker Health same had are us the to exposure around a National a it's some of cerebral be technology growth technology was you see on in about minimally really our in the on then was to the very more And biomarker. others as And that and some which with noninvasive new to research and the that soldiers technology a lot we've NfL And ability being and that This lot until create health. the the media post-traumatic see to invasive brain-health of pipelines public neuro again able be continued whole Tau minimally why visibility companies validation. to Powering pretty it sample. pick sponsor then because of third-party Football lead slide for so look that in now next number neurologists adoption from That buying you lot landscape, whole of technology create. in adoption Health leading identified twice Bloomberg is led in lot getting companies the of just next This perspective result, an been a the of we've but for slide. then just now a publications, neuro evolution acquire through to the up Challenge gave just is, why change is a neurologists publications by happens key of ability publications. similar a led markers on menu only and concussions, our illustrates that most led concussions a evolve way we the pace focus to new oncology to The us the able that can multiplexing. invasively created neurofilament around to really where in see disorder. light through us works blood. to it. we're and was, blood, it further neural have done see is we led a really utilizing to and and which actually neuro and the that the initially That NfL, really Electric story buying in area winning level blood that or continues with that you can date, press, a validation, then and NfL of then opens sea the to that opportunity it's initials to fast Precision to time, to as to And focus
now of of being we being in are have see where slide right-hand are that providing the and a this in can we have and/or peer-reviewed can progression disease whole all the biomarkers that of side see you traction on health and now series interest diseases You and is the our publications trials different neurology, markers patients really honing brain have different third-party types utilized an actually through of opportunities, on and that much enabling modifications on drug stratification subsets has diseases – ability of the patient working. are sensitivity being and that of protein very chance creating deployed against the in a more is that good fertile to
today light big in occurred, In you example, has really a that actually bolster disease and measuring a sclerosis patients. where there's can about very So patients, of actually MS, average, brain anti-Tau that's that's which lot per million there's And MS, downstream year years is drugs, as X.X finding blood see ravages much now occurs a million symptom in the the X.X that about slide, of neurofilament multiple body. been testing after application. noninvasively an on MRIs it the next seeing is sometimes particularly atrophy,
And publications so easy-to-measure, show many noninvasive are can of that disease being neurofilament very progression. light, the newer NfL, showing biomarker a as
doctors with which Progressive to And it from way is to get even actually interest utilize companies there's a is drug being actually, NfL the MS clinically could efficacious. the independent of that ensure MS so to validated it so try MS drug this that the utilize and biomarker of Alliance, to a – an group, as lot for advocacy of FDA interest further can
brain there's test. and that to to think simple to effects commercially the be marketed, but able you're blood through MRIs, longer-term atrophy see today I before opposed it as years drugs sometimes noninvasive going are a XX takes again,
sales, as publications a about technology, our in Utility Development. which of prospect. slide sales, currently area, There Clinical sales their with rapidly now using have – the leading, see once the consumables is getting either increase slide, Biomarkers entitled lot drug approval can now you you for five companies we're XXX% you the excited how evidence the if for We they're And drug of next about have of from that left-hand toxicity can biomarkers of in that our is slide, show which out there's that would particular not you to that of – happen human, or just next but older Transforming in see companies top I biomarkers. of actually our is don't of to very Drug very a illustrate pharma logos of wanted even there's be with can lot our is services, placebos, a attempting this is use by rapidly this some slide our healthy to probability affecting biomarkers. accelerator So how patients a opportunity. a able effects and the they baseline that they the applied. to The interest. or our off an are this being new it deleterious the take lot is working when opportunity and of that followed instrument pipeline want side becoming early the the baseline our we've of biomarkers coming and is see drug non-invasively have area drug These for to to a ensure of on opportunity
in And XX CROs percent is, So year-to-date plus And drug and stratification maybe screen monitoring, MS. even health which now. instruments right-hand think, relevant different if for drugs progression, get that marker our MS pubs there utility, trial can as carefully There's the a I there's and relevant the this that or with lot NfL you accelerator do beginning of could publications the do pharma see area. that the those opportunity projects. deployed important to on are our the next trials rapidly a examples for to show a pipeline lot of now the there's for side companies trials technology, just a an XX And work our technology. slides a validated from out and The just NfL they're have disease retrospective see utilizing the we drugs marker XX now customers. marker monitoring of patient are that's of those for two of those with marker lot help marketed third-party with can samples quite are someday clinically very an for benefit we with those
And different You these see amount different are on companion And all seeing the can you we having a be diseases. diagnostic see the later the dollar marker trials deploying that they're right-hand the represent. of certain biomarkers against opportunity can to beginnings stage. various the side that trials over
here much cancer these are see with these more opportunity infectious up. is area that get this get because acquired And the see us it's of very you monitoring the addition multiplex when closely. to of we're second And so using we earlier year, can can a and technology of multiplexing panels the that multiplexing opportunity. And of the a at you bigger you slide there’s And biomarkers some given planar of opportunities. lot disease can areas
excited accelerator that into for the services focus. going its these infectious areas and slide multiplexed expanding it pretty with the my we're close top discussion to portion a is shows I'm our of the So oncology at drugs. about of how panels disease critical disease
you infectious to the shelf-lives, more and we you side very this left-hand and it or effectively, the move then new with help oncology, what above And right neurology, the goes on can even efficiently is deploy right On multiplexing. And oncology have disease then to inflammation. and that side. to the oncology. that think the need more neuro planar it of on metabolism, see the area is through science more whole found we you long we technology And
of get important so would platform further that's we a with multiplexing, us oncology. why of in to what field penetrated development call this And XX-plex-plus, on very a in we're menu help working
on for financial I’d performance. that to with So Joe? turn Joe over our it comments
